OBJECTIVE: The objective of this study was to evaluate the association of urine clusterin/apolipoprotein J (Apo J) with the development and/or progression of diabetic kidney disease (DKD) in type 2 diabetes. MATERIALS AND METHODS: A total of 159 type 2 diabetic patients and 20 nondiabetic subjects with estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m2 were enrolled. The baseline values of urine clusterin and tubular damage markers were measured. The primary outcome was the annual decline rate in eGFR, and secondary outcomes were the development of chronic kidney disease (CKD) stage 3 or greater and the persistence/progression of albuminuria. The median follow-up duration of enrolled patients was 3.0 (1.0-5.9) years. RESULTS: Baseline clusterin levels in urine were significantly increased in type 2 diabetic subjects compared with those of nondiabetic subjects. The levels of urine clusterin had a significant correlation with urine tubular damage markers. A positive correlation between the annual rate of decline in eGFR and urine clusterin after adjusting for clinical confounding factors was detected. Multivariate analysis further indicated that urine clusterin correlated with the development of CKD stage 3 or greater and persistence/progression of albuminuria. In type 2 diabetic subjects with albuminuria, urine clusterin remained associated with the annual decline rate in eGFR and the progression of CKD stage. CONCLUSIONS: Urine clusterin reflects tubular damage in the early stage of DKD. The increase in urine clusterin along with albuminuria could be an independent predictive marker for the progression of DKD in type 2 diabetes.
OBJECTIVE: The objective of this study was to evaluate the association of urine clusterin/apolipoprotein J (Apo J) with the development and/or progression of diabetic kidney disease (DKD) in type 2 diabetes. MATERIALS AND METHODS: A total of 159 type 2 diabeticpatients and 20 nondiabetic subjects with estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m2 were enrolled. The baseline values of urine clusterin and tubular damage markers were measured. The primary outcome was the annual decline rate in eGFR, and secondary outcomes were the development of chronic kidney disease (CKD) stage 3 or greater and the persistence/progression of albuminuria. The median follow-up duration of enrolled patients was 3.0 (1.0-5.9) years. RESULTS: Baseline clusterin levels in urine were significantly increased in type 2 diabetic subjects compared with those of nondiabetic subjects. The levels of urine clusterin had a significant correlation with urine tubular damage markers. A positive correlation between the annual rate of decline in eGFR and urine clusterin after adjusting for clinical confounding factors was detected. Multivariate analysis further indicated that urine clusterin correlated with the development of CKD stage 3 or greater and persistence/progression of albuminuria. In type 2 diabetic subjects with albuminuria, urine clusterin remained associated with the annual decline rate in eGFR and the progression of CKD stage. CONCLUSIONS: Urine clusterin reflects tubular damage in the early stage of DKD. The increase in urine clusterin along with albuminuria could be an independent predictive marker for the progression of DKD in type 2 diabetes.
Authors: Andrew N Hoofnagle; Mingyuan Wu; Albina K Gosmanova; Jessica O Becker; Ellen M Wijsman; John D Brunzell; Steven E Kahn; Robert H Knopp; Timothy J Lyons; Jay W Heinecke Journal: Arterioscler Thromb Vasc Biol Date: 2010-09-16 Impact factor: 8.311
Authors: Sang Soo Kim; Sang Heon Song; In Joo Kim; Yun Kyung Jeon; Bo Hyun Kim; Ihm Soo Kwak; Eun Kyung Lee; Yong Ki Kim Journal: Diabetes Care Date: 2012-10-23 Impact factor: 19.112
Authors: Joshua Y C Yang; Reuben D Sarwal; Tara K Sigdel; Izabella Damm; Ben Rosenbaum; Juliane M Liberto; Chitranon Chan-On; José M Arreola-Guerra; Josefina Alberu; Flavio Vincenti; Minnie M Sarwal Journal: Sci Transl Med Date: 2020-03-18 Impact factor: 17.956
Authors: Drew Watson; Joshua Y C Yang; Reuben D Sarwal; Tara K Sigdel; Juliane M Liberto; Izabella Damm; Victoria Louie; Shristi Sigdel; Devon Livingstone; Katherine Soh; Arjun Chakraborty; Michael Liang; Pei-Chen Lin; Minnie M Sarwal Journal: J Clin Med Date: 2019-04-12 Impact factor: 4.241
Authors: Junling He; Kyra L Dijkstra; Kim Bakker; Pascal Bus; Jan A Bruijn; Marion Scharpfenecker; Hans J Baelde Journal: Sci Rep Date: 2020-09-10 Impact factor: 4.379